Singapore markets open in 3 hours 31 minutes
  • Straits Times Index

    3,111.65
    +18.85 (+0.61%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow

    31,500.68
    +823.28 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.42 (+3.34%)
     
  • BTC-USD

    21,333.08
    -44.13 (-0.21%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Gold

    1,828.10
    -2.20 (-0.12%)
     
  • Crude Oil

    107.06
    -0.56 (-0.52%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Nikkei

    26,491.97
    +320.77 (+1.23%)
     
  • Hang Seng

    21,719.06
    +445.16 (+2.09%)
     
  • FTSE Bursa Malaysia

    1,436.70
    +5.65 (+0.39%)
     
  • Jakarta Composite Index

    7,042.94
    +44.67 (+0.64%)
     
  • PSE Index

    6,217.56
    +152.33 (+2.51%)
     

Lonza's full-year core EBITDA up 20.7% on vaccine demand

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: Logo of Swiss contract drug maker Lonza is seen in Basel
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines.

Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. That was broadly in line with an analyst consensus posted on its website.

The company, which is a key supplier of vaccine maker Moderna, is stepping up investments as it banks on long-term growth in the biopharmaceuticals sector well beyond the pandemic. [nL8N2R81GF]

For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.

(Reporting by Ludwig BurgerEditing by Riham Alkousaa, editing by Kirsti Knolle)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting